Oxford Biomedica Regulatory News (OXB)

25 Jan 2005 09:35

Garboldi Investment Ltd25 January 2005 Date of Disclosure 25 JANUARY 2005 DISCLOSURE UNDER RULES 8.1(a), 8.1(b)(i) and 8.3 OF THE CITY CODE ON TAKEOVERS AND MERGERS Date of dealing JANUARY 24, 2005 Dealing in OXFORD BIOMEDICA PLC (name of company) 1) Class of securities (eg ordinary shares) ORDINARY SHARES 2) Amount bought Amount sold Price per unit 83,333 - 0.221100 GBP 3) Resultant total of the same class owned or controlled (and percentage of class) 3,983,332 (1.0760 %) 4) Party making disclosure GARBOLDI INVESTMENT LIMITED 5) EITHER (a) Name of purchaser/vendor (Note 1) GARBOLDI INVESTMENT LIMITED OR (b) if dealing for discretionary client(s), name of fund management organisation 6) Reason for disclosure (Note 2) (a) associate of (i) offeror (Note 3) NO (ii) offeree company NO Specify which category or categories of associate (1-8 overleaf) If category (8), explain (b) Rule 8.3 (ie disclosure because of ownership or control of 1% or more of the class of relevant securities dealt in) YES Signed, for and on behalf of the party named in (4) above N/A (Also print name of signatory) PETER CLATEMAN Telephone and extension number +7 095 725 5019 Note 1. Specify owner, not nominee or vehicle company. If relevant, also identify controller of owner, eg where an owner normally acts on instructions of a controller Note 2. Disclosure might be made for more than one reason; if so, state all reasons. Note 3. Specify which offeror if there is more than one. Note 4. When an arrangement exists with any offeror, with the offeree company or which an associate of any offeror or of the offeree company in relation to relevant securities, details of such arrangement must be disclosed, as required by Note 6 on Rule 8 Note 5. It may be necessary, particularly when disclosing derivative transactions, to append a sheet to this disclosure form so that relevant information can be given. Note 6. In the case of an average price bargain, each underlying trade should be disclosed. Note 7. The resultant total percentage holding of the class of relevant security is to be calculated by reference to the percentage held and in issue outside treasury. For full details of disclosure requirements, see Rule 8 of the Code. If in doubt, contact the Panel on Takeovers and Mergers, Monitoring Section, Tel. No:020 7638 0129. Email: monitoring@disclosure.org.uk END This information is provided by RNS The company news service from the London Stock Exchange